KA/EN
Register
Medicines reference
Search
Search
Active substance

Bedinvetmab

Favourites

Anti-NGF monoclonal antibody. Registered in Georgia: 5 veterinary products. Forms: solution.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Bedinvetmab
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
0.5–1 mg/kg Dog Pain Associated with Osteoarthritis
Analgesia
 Subcutaneous monthly
EMA SPC 2026
Official product label (SPC), EMA, EU
Approved by the European Medicines Agency (EMA) as part of the product's authorisation. It applies to that product as authorised there.
Librela 5/10/15/20/30 mg solution for injection for dogs - EU product information (SPC and package leaflet)
European Medicines Agency / Union Product Database, 2026
Before use

Safety information

Known Contraindications

  • Critical
    Do not use in dogs hypersensitive to bedinvetmab or any excipient.
    Sources: Librela EU SPC
  • Critical
    Do not use in dogs under 12 months of age.
    Sources: Librela EU SPC
  • Critical
    Do not use in pregnant bitches: anti-NGF antibodies were teratogenic and foetotoxic in monkey studies.
    Sources: Librela EU SPC
  • Critical
    Do not use in lactating bitches.
    Sources: Librela EU SPC
  • Warning
    Do not use in dogs intended for breeding.
    Sources: Librela EU SPC
  • Caution
    Use with caution in dogs with a pre-existing seizure disorder.
    Sources: Librela EU SPC
  • Caution
    Use with caution in immune-mediated haemolytic anaemia, polyarthritis or thrombocytopenia. New or worse joint swelling or pain after treatment needs investigation and may mean stopping. No safety data on long-term use with NSAIDs.
    Sources: Librela EU SPC
Latin name
Bedinvetmab
Georgian name
ბედინვეტმაბი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
5 of 5 forms
Products
Librela
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
All forms and registration5

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Librela, Solution

Bedinvetmab 5 mg/ml, solution for injection for dogs (1 ml vial)
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.8/10
Good
vetman assessment

Librela

Bedinvetmab 5 mg/ml, solution for injection for dogs (1 ml vial)
Assessed clinical scopeDog · Full labelled canine indication: alleviation of pain associated with osteoarthritis · Subcutaneous
Care settingVeterinarian-administered monthly analgesia within multimodal osteoarthritis management, with response and adverse-event reassessment before repeat dosing
vetman score 7.8/10 Good
Evidence confidence: High Georgia: Yes, veterinary · Verified on 18 Oct 2026

A useful monthly osteoarthritis analgesic with demonstrated benefit and major adherence advantages, but not a routine automatic repeat injection: confirm meaningful response and actively screen for current postmarketing safety signals before every dose.

Regulatory and scientific credibility9.5/10

All five exact strengths are centrally authorised in the EU, supported by current product information and pharmacovigilance updates, FDA authorisation and active Georgian veterinary registration.

Clinical efficacy7.5/10

Two pivotal placebo-controlled field trials show statistically significant pain and function benefit, but first-dose absolute response is moderate, owner-reported outcomes have a substantial placebo component and nonresponse must be recognised early.

Safety and tolerability6.0/10

Premarketing trials were broadly reassuring, but post-authorisation signals include neurologic signs, urinary changes, polyuria/polydipsia, joint swelling or pain and reports with death or euthanasia outcomes; causality is not established for every spontaneous report.

Clinical practicality8.5/10

Once-monthly subcutaneous administration avoids daily tablets and renal/hepatic drug clearance concerns, but requires clinic attendance, exact weight-band vial selection and structured reassessment before each injection.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Before every repeat injection, ask specifically about new or worsening ataxia, weakness, seizures, recumbency, urinary incontinence, polyuria/polydipsia and other neurologic or urinary changes; investigate and reconsider treatment if present.
  • If new or increased joint swelling or joint pain develops, perform additional diagnostics and discontinue or continue only after an individual reassessment.
  • Do not use during pregnancy or lactation or in breeding animals; safety and efficacy in dogs younger than 12 months have not been established.
  • Reassess objective mobility, pain interference and quality of life after the first and second doses; stop serial dosing when clinically meaningful benefit is absent.
  • Build a gradual return-to-activity plan and use within multimodal osteoarthritis care; analgesia can permit overactivity before muscle strength and joint capacity recover.
Assessment sources
  1. EMA SPC 20262026
  2. EMA Librela EPAR2026
  3. Librela EU pivotal RCT2021
  4. Librela US pivotal RCT2023
  5. FDA Librela safety letter2024
  6. EMA Librela pharmacovigilance 20262026
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Bedinvetmab5 mg/ml
Formulation Type
Solution
Administration route
Subcutaneous
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ლიბრელა 5მგ
Verified on: 18 Oct 2026
 EU Yes, veterinary
№ EU/2/20/261
Verified on: 18 Oct 2026
 UK Yes, veterinary
№ Vm 42058/5029
Verified on: 18 Oct 2026
 US Yes, veterinary
№ NADA 141-562
Verified on: 18 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026

Librela, Solution

Bedinvetmab 10 mg/ml, solution for injection for dogs (1 ml vial)
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.8/10
Good
vetman assessment

Librela

Bedinvetmab 10 mg/ml, solution for injection for dogs (1 ml vial)
Assessed clinical scopeDog · Full labelled canine indication: alleviation of pain associated with osteoarthritis · Subcutaneous
Care settingVeterinarian-administered monthly analgesia within multimodal osteoarthritis management, with response and adverse-event reassessment before repeat dosing
vetman score 7.8/10 Good
Evidence confidence: High Georgia: Yes, veterinary · Verified on 18 Oct 2026

A useful monthly osteoarthritis analgesic with demonstrated benefit and major adherence advantages, but not a routine automatic repeat injection: confirm meaningful response and actively screen for current postmarketing safety signals before every dose.

Regulatory and scientific credibility9.5/10

All five exact strengths are centrally authorised in the EU, supported by current product information and pharmacovigilance updates, FDA authorisation and active Georgian veterinary registration.

Clinical efficacy7.5/10

Two pivotal placebo-controlled field trials show statistically significant pain and function benefit, but first-dose absolute response is moderate, owner-reported outcomes have a substantial placebo component and nonresponse must be recognised early.

Safety and tolerability6.0/10

Premarketing trials were broadly reassuring, but post-authorisation signals include neurologic signs, urinary changes, polyuria/polydipsia, joint swelling or pain and reports with death or euthanasia outcomes; causality is not established for every spontaneous report.

Clinical practicality8.5/10

Once-monthly subcutaneous administration avoids daily tablets and renal/hepatic drug clearance concerns, but requires clinic attendance, exact weight-band vial selection and structured reassessment before each injection.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Before every repeat injection, ask specifically about new or worsening ataxia, weakness, seizures, recumbency, urinary incontinence, polyuria/polydipsia and other neurologic or urinary changes; investigate and reconsider treatment if present.
  • If new or increased joint swelling or joint pain develops, perform additional diagnostics and discontinue or continue only after an individual reassessment.
  • Do not use during pregnancy or lactation or in breeding animals; safety and efficacy in dogs younger than 12 months have not been established.
  • Reassess objective mobility, pain interference and quality of life after the first and second doses; stop serial dosing when clinically meaningful benefit is absent.
  • Build a gradual return-to-activity plan and use within multimodal osteoarthritis care; analgesia can permit overactivity before muscle strength and joint capacity recover.
Assessment sources
  1. EMA SPC 20262026
  2. EMA Librela EPAR2026
  3. Librela EU pivotal RCT2021
  4. Librela US pivotal RCT2023
  5. FDA Librela safety letter2024
  6. EMA Librela pharmacovigilance 20262026
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Bedinvetmab10 mg/ml
Formulation Type
Solution
Administration route
Subcutaneous
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ლიბრელა 10მგ
Verified on: 18 Oct 2026
 EU Yes, veterinary
№ EU/2/20/261
Verified on: 18 Oct 2026
 UK Yes, veterinary
№ Vm 42058/5029
Verified on: 18 Oct 2026
 US Yes, veterinary
№ NADA 141-562
Verified on: 18 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026

Librela, Solution

Bedinvetmab 15 mg/ml, solution for injection for dogs (1 ml vial)
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.8/10
Good
vetman assessment

Librela

Bedinvetmab 15 mg/ml, solution for injection for dogs (1 ml vial)
Assessed clinical scopeDog · Full labelled canine indication: alleviation of pain associated with osteoarthritis · Subcutaneous
Care settingVeterinarian-administered monthly analgesia within multimodal osteoarthritis management, with response and adverse-event reassessment before repeat dosing
vetman score 7.8/10 Good
Evidence confidence: High Georgia: Yes, veterinary · Verified on 18 Oct 2026

A useful monthly osteoarthritis analgesic with demonstrated benefit and major adherence advantages, but not a routine automatic repeat injection: confirm meaningful response and actively screen for current postmarketing safety signals before every dose.

Regulatory and scientific credibility9.5/10

All five exact strengths are centrally authorised in the EU, supported by current product information and pharmacovigilance updates, FDA authorisation and active Georgian veterinary registration.

Clinical efficacy7.5/10

Two pivotal placebo-controlled field trials show statistically significant pain and function benefit, but first-dose absolute response is moderate, owner-reported outcomes have a substantial placebo component and nonresponse must be recognised early.

Safety and tolerability6.0/10

Premarketing trials were broadly reassuring, but post-authorisation signals include neurologic signs, urinary changes, polyuria/polydipsia, joint swelling or pain and reports with death or euthanasia outcomes; causality is not established for every spontaneous report.

Clinical practicality8.5/10

Once-monthly subcutaneous administration avoids daily tablets and renal/hepatic drug clearance concerns, but requires clinic attendance, exact weight-band vial selection and structured reassessment before each injection.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Before every repeat injection, ask specifically about new or worsening ataxia, weakness, seizures, recumbency, urinary incontinence, polyuria/polydipsia and other neurologic or urinary changes; investigate and reconsider treatment if present.
  • If new or increased joint swelling or joint pain develops, perform additional diagnostics and discontinue or continue only after an individual reassessment.
  • Do not use during pregnancy or lactation or in breeding animals; safety and efficacy in dogs younger than 12 months have not been established.
  • Reassess objective mobility, pain interference and quality of life after the first and second doses; stop serial dosing when clinically meaningful benefit is absent.
  • Build a gradual return-to-activity plan and use within multimodal osteoarthritis care; analgesia can permit overactivity before muscle strength and joint capacity recover.
Assessment sources
  1. EMA SPC 20262026
  2. EMA Librela EPAR2026
  3. Librela EU pivotal RCT2021
  4. Librela US pivotal RCT2023
  5. FDA Librela safety letter2024
  6. EMA Librela pharmacovigilance 20262026
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Bedinvetmab15 mg/ml
Formulation Type
Solution
Administration route
Subcutaneous
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ლიბრელა 15მგ
Verified on: 18 Oct 2026
 EU Yes, veterinary
№ EU/2/20/261
Verified on: 18 Oct 2026
 UK Yes, veterinary
№ Vm 42058/5029
Verified on: 18 Oct 2026
 US Yes, veterinary
№ NADA 141-562
Verified on: 18 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026

Librela, Solution

Bedinvetmab 20 mg/ml, solution for injection for dogs (1 ml vial)
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.8/10
Good
vetman assessment

Librela

Bedinvetmab 20 mg/ml, solution for injection for dogs (1 ml vial)
Assessed clinical scopeDog · Full labelled canine indication: alleviation of pain associated with osteoarthritis · Subcutaneous
Care settingVeterinarian-administered monthly analgesia within multimodal osteoarthritis management, with response and adverse-event reassessment before repeat dosing
vetman score 7.8/10 Good
Evidence confidence: High Georgia: Yes, veterinary · Verified on 18 Oct 2026

A useful monthly osteoarthritis analgesic with demonstrated benefit and major adherence advantages, but not a routine automatic repeat injection: confirm meaningful response and actively screen for current postmarketing safety signals before every dose.

Regulatory and scientific credibility9.5/10

All five exact strengths are centrally authorised in the EU, supported by current product information and pharmacovigilance updates, FDA authorisation and active Georgian veterinary registration.

Clinical efficacy7.5/10

Two pivotal placebo-controlled field trials show statistically significant pain and function benefit, but first-dose absolute response is moderate, owner-reported outcomes have a substantial placebo component and nonresponse must be recognised early.

Safety and tolerability6.0/10

Premarketing trials were broadly reassuring, but post-authorisation signals include neurologic signs, urinary changes, polyuria/polydipsia, joint swelling or pain and reports with death or euthanasia outcomes; causality is not established for every spontaneous report.

Clinical practicality8.5/10

Once-monthly subcutaneous administration avoids daily tablets and renal/hepatic drug clearance concerns, but requires clinic attendance, exact weight-band vial selection and structured reassessment before each injection.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Before every repeat injection, ask specifically about new or worsening ataxia, weakness, seizures, recumbency, urinary incontinence, polyuria/polydipsia and other neurologic or urinary changes; investigate and reconsider treatment if present.
  • If new or increased joint swelling or joint pain develops, perform additional diagnostics and discontinue or continue only after an individual reassessment.
  • Do not use during pregnancy or lactation or in breeding animals; safety and efficacy in dogs younger than 12 months have not been established.
  • Reassess objective mobility, pain interference and quality of life after the first and second doses; stop serial dosing when clinically meaningful benefit is absent.
  • Build a gradual return-to-activity plan and use within multimodal osteoarthritis care; analgesia can permit overactivity before muscle strength and joint capacity recover.
Assessment sources
  1. EMA SPC 20262026
  2. EMA Librela EPAR2026
  3. Librela EU pivotal RCT2021
  4. Librela US pivotal RCT2023
  5. FDA Librela safety letter2024
  6. EMA Librela pharmacovigilance 20262026
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Bedinvetmab20 mg/ml
Formulation Type
Solution
Administration route
Subcutaneous
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ლიბრელა 20მგ
Verified on: 18 Oct 2026
 EU Yes, veterinary
№ EU/2/20/261
Verified on: 18 Oct 2026
 UK Yes, veterinary
№ Vm 42058/5029
Verified on: 18 Oct 2026
 US Yes, veterinary
№ NADA 141-562
Verified on: 18 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026

Librela, Solution

Bedinvetmab 30 mg/ml, solution for injection for dogs (1 ml vial)
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.8/10
Good
vetman assessment

Librela

Bedinvetmab 30 mg/ml, solution for injection for dogs (1 ml vial)
Assessed clinical scopeDog · Full labelled canine indication: alleviation of pain associated with osteoarthritis · Subcutaneous
Care settingVeterinarian-administered monthly analgesia within multimodal osteoarthritis management, with response and adverse-event reassessment before repeat dosing
vetman score 7.8/10 Good
Evidence confidence: High Georgia: Yes, veterinary · Verified on 18 Oct 2026

A useful monthly osteoarthritis analgesic with demonstrated benefit and major adherence advantages, but not a routine automatic repeat injection: confirm meaningful response and actively screen for current postmarketing safety signals before every dose.

Regulatory and scientific credibility9.5/10

All five exact strengths are centrally authorised in the EU, supported by current product information and pharmacovigilance updates, FDA authorisation and active Georgian veterinary registration.

Clinical efficacy7.5/10

Two pivotal placebo-controlled field trials show statistically significant pain and function benefit, but first-dose absolute response is moderate, owner-reported outcomes have a substantial placebo component and nonresponse must be recognised early.

Safety and tolerability6.0/10

Premarketing trials were broadly reassuring, but post-authorisation signals include neurologic signs, urinary changes, polyuria/polydipsia, joint swelling or pain and reports with death or euthanasia outcomes; causality is not established for every spontaneous report.

Clinical practicality8.5/10

Once-monthly subcutaneous administration avoids daily tablets and renal/hepatic drug clearance concerns, but requires clinic attendance, exact weight-band vial selection and structured reassessment before each injection.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Before every repeat injection, ask specifically about new or worsening ataxia, weakness, seizures, recumbency, urinary incontinence, polyuria/polydipsia and other neurologic or urinary changes; investigate and reconsider treatment if present.
  • If new or increased joint swelling or joint pain develops, perform additional diagnostics and discontinue or continue only after an individual reassessment.
  • Do not use during pregnancy or lactation or in breeding animals; safety and efficacy in dogs younger than 12 months have not been established.
  • Reassess objective mobility, pain interference and quality of life after the first and second doses; stop serial dosing when clinically meaningful benefit is absent.
  • Build a gradual return-to-activity plan and use within multimodal osteoarthritis care; analgesia can permit overactivity before muscle strength and joint capacity recover.
Assessment sources
  1. EMA SPC 20262026
  2. EMA Librela EPAR2026
  3. Librela EU pivotal RCT2021
  4. Librela US pivotal RCT2023
  5. FDA Librela safety letter2024
  6. EMA Librela pharmacovigilance 20262026
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Bedinvetmab30 mg/ml
Formulation Type
Solution
Administration route
Subcutaneous
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ლიბრელა 30მგ
Verified on: 18 Oct 2026
 EU Yes, veterinary
№ EU/2/20/261
Verified on: 18 Oct 2026
 UK Yes, veterinary
№ Vm 42058/5029
Verified on: 18 Oct 2026
 US Yes, veterinary
№ NADA 141-562
Verified on: 18 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 18 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗